Cancer cells shed fragments of DNA into the blood known as circulating tumor DNA (ctDNA).

LucenceINSIGHT™ uses proprietary technology to amplify and identify signs of ctDNA in the bloodstream.

The result is cross examined with machine-learning to study the cancer signal profile and provide insights on where the ctDNA might have originated from.

LucenceINSIGHT™ is recommended in conjunction with existing screening tools for:

• Individuals aged 40 and above without personal history of cancer
• Individuals with elevated cancer risk (eg, family history of cancer)

LucenceINSIGHT™ investigates alterations that are found in the genes. Genes are instructions for the cells to grow and function and changes (mutations) to the genes sometimes cause the growth functions to go out of control, leading to cancer.

Cancer marker tests such as CA19-9 or CA125 look for the presence of proteins which are made in higher amounts by cancer cells.

Overall, gene mutations and protein markers have a ‘cause and effect’ relationship when it comes to cancer detection. LucenceINSIGHT™ should be used in addition to routine cancer screening tools offered by your healthcare provider to bring clarity in early cancer screening.

Please contact your healthcare provider to order a LucenceINSIGHT™ test.

If your doctor does not offer LucenceINSIGHT™ at their practice, kindly reach out to us and we will make the introductions.

Annual screening is recommended. 

However, it is up to your healthcare provider to determine an appropriate screening interval based on your existing medical risks.

LucenceINSIGHT™ is intended for the screening of cancer signal of asymptomatic patients.The results of the analysis will be affected if users have a history of cancer.  

If you are a patient with a history of cancer, LiquidHALLMARK® is the recommended test. Read more about LiquidHALLMARK® here.